Akamai Technologies (NASDAQ:AKAM) shareholders have endured a 26% loss from investing in the stock three years ago
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term Akamai Technologies, Inc. (NASDAQ:AKAM) shareholders, since the share price is down 26% in the last three years, falling well short of the market return of around 46%.
So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
Akamai Technologies saw its EPS decline at a compound rate of 7.3% per year, over the last three years. The share price decline of 10% is actually steeper than the EPS slippage. So it seems the market was too confident about the business, in the past.
The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).
We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. Dive deeper into the earnings by checking this interactive graph of Akamai Technologies' earnings, revenue and cash flow.
Akamai Technologies shareholders are down 16% for the year, but the market itself is up 14%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 5% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Akamai Technologies you should be aware of.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
News Corp Extends Contract with Chief Executive Robert Thomson
NEW YORK--(BUSINESS WIRE)--News Corp (NASDAQ: NWS, NWSA; ASX: NWS; NWSLV) announced today the extension of Robert Thomson's contract, which will see him continue as Chief Executive through June 2030. The extension is a recognition of Mr. Thomson's exceptional track record of transformational leadership, value creation and effective advocacy for journalism and intellectual property protection. Since Mr. Thomson's appointment as Chief Executive in 2013, News Corp has undergone significant transformation, with a focus on strategic investments in its core growth pillars—Dow Jones, Digital Real Estate Services and Book Publishing—and delivered its four most profitable years from fiscal 2021 to 2024, with continued strong performance in fiscal 2025. During this period of dramatic change across media and technology, News Corp has thrived, while many other media entities have floundered. Under Mr. Thomson's leadership, News Corp: Transformed its revenue base with a focus on recurring and digital revenues, materially reducing exposure to cyclical advertising (digital revenues account for 50% of total revenues as of fiscal 2024 compared to roughly 20% in 2014) Reshaped its portfolio, particularly with the 2020 re-segmentation of Dow Jones, which has since doubled in profitability, and the sale of Foxtel to DAZN in April of this year Signed landmark agreements with major technology platforms, including most recently with OpenAI, to license the company's intellectual property in exchange for meaningful compensation Achieved an Investment Grade Credit rating across all key credit agencies, driven by improved asset mix and a pristine balance sheet Completed key acquisitions of OPIS and Base Chemicals at Dow Jones, making its B2B offering the largest contributor to segment profitability in fiscal 2024 and a key driver of expected future growth Oversaw the strong performance in Book Publishing, including growth in audiobooks supported by the strategic partnership with Spotify 'Robert has been instrumental in News Corp's growth and transformation, and his vision and leadership are extremely important as the company continues to navigate this era of rapid change,' said News Corp Chair Lachlan Murdoch. 'Robert has created exceptional shareholder value, orchestrated a meaningful transformation of our asset base, and made strategic investments in growth drivers like Dow Jones, Digital Real Estate Services and Book Publishing. He is a crucial voice in the fight for publishers and journalists in the digital age, and a strong advocate for intellectual property rights. I look forward to his continued leadership.'
Business Wire
an hour ago
- Business Wire
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.
Newsweek
an hour ago
- Newsweek
How Could Strait of Hormuz Closure Impact Americans?
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Iranian lawmakers have voted to support closing the Strait of Hormuz—a vital route for global oil and gas shipments—in response to U.S. airstrikes on three of the country's nuclear sites on Saturday, a move that if agreed upon by the Supreme Leader, could disrupt energy markets and drive up prices worldwide and stateside. Why It Matters Following U.S. strikes on three Iranian nuclear sites, Isfahan, Fordow, and Natanz, the world waits as Iran considers its response. The Strait of Hormuz is a narrow, yet incredibly strategic waterway connecting the Persian Gulf to the Gulf of Oman and the Arabian Sea. At its narrowest point, the strait is about 21 miles wide, with two shipping lanes that are 2 miles wide in each direction. Around 20 percent of global oil trade passes through the Strait, with any closure likely to spike global prices. What To Know In the first fiscal quarter of 2025, the U.S. Energy Information Agency (EIA) noted that just under 15 million barrels of crude oil and condensate, and about 8 million barrels of petroleum products were transported through the Strait. There are very few alternative routes for the large volume of oil that passes through the chokepoint. The average 20 million barrels of oil products that pass through make up around 20 percent of the global consumption. The price of Brent crude oil was already climbing ahead of the U.S. strikes, increasing from $69 per barrel on June 12 to $74 per barrel on June 13. While the EIA estimates that a large majority, around 80 percent, of the oil-based product moving through the Strait go to Asian markets, around 2 million barrels a day end up in the U.S. Stena Impero being seized and detained between July 19 and July 21, 2019 in Bandar Abbas, Iran as it passed through the Strait of Hormuz, a vital regional shipping channel. Stena Impero being seized and detained between July 19 and July 21, 2019 in Bandar Abbas, Iran as it passed through the Strait of Hormuz, a vital regional shipping channel. Tasnim/Getty Images If the Iranian government following the lead of the parliament, decides to close the Strait, Asian markets are expected to be most hit, but American markets will be too. Despite influence over the Strait, Iran doesn't supply the most oil that transports through it, Saudi Arabia does. Some experts have said that if Iran were to cut off access to the Strait, it could spike oil prices by 30 to 50 percent immediately, with gas prices likewise rising. "Oil prices would likely double, to well above $100. The extent to which that price shock would be sustainable is unclear," Marko Papic, chief strategist at BCA Research, told Newsweek in an email Sunday. He also noted that due to the overwhelming pressure campaign the country would face over its closure "the price shock would be of limited duration." "However," he continued, "it could impact confidence domestically, impact capex [capital expenditure] intentions by corporates, and thus trickle into the animal spirits [psychological factors that influence economic behavior] that affects not just stocks, but also the labor market." Fears that Iran could attack U.S. oil infrastructure in the region and levy its power over the Straits of Hormuz could "combine to make prices and speculation rise about the security and dependability of supply," Greg Kennedy, director of the Economic Conflict and Competition Research Group at King's College London, previously told Newsweek. "Lack of clarity of how long this condition will last will also lead to hoarding or preemptive purchasing by other nations, so there are competition supply fears that will drive up prices," he added. Iran has been reluctant to close to Strait, even during times of intense conflict during the heat of the Iran-Iraq war. Infographic with map of the Gulf showing maritime tanker traffic in September 2024 through the Strait of Hormuz. Infographic with map of the Gulf showing maritime tanker traffic in September 2024 through the Strait of Hormuz. NALINI LEPETIT-CHELLA,OMAR KAMAL/AFP via Getty Images) What People Are Saying Greg Kennedy, director of the Economic Conflict and Competition Research Group at King's College London, told Newsweek: "This is not an act that just stays in the Gulf region, it has wider global strategic ripples." Spencer Hakimian, founder of Tolou Capital Management, wrote on X, formerly Twitter, on Saturday: "There are close to 50 large oil tankers scrambling to leave the Strait of Hormuz right now. Looks like the oil industry is expecting the Strait to be blockaded in the coming days." President Donald Trump wrote on Truth Social on Saturday evening: "ANY RETALIATION BY IRAN AGAINST THE UNITED STATES OF AMERICA WILL BE MET WITH FORCE FAR GREATER THAN WHAT WAS WITNESSED TONIGHT. THANK YOU! DONALD J. TRUMP, PRESIDENT OF THE UNITED STATES." Brian Krassenstein, who has over 900,000 followers on X wrote on Sunday if the Strait is closed, people can expect: "U.S. Gas Prices likely Skyrocket. Potential $5–$7/gallon range depending on duration. Military Escalation Risk. U.S. Navy and allies likely to respond. Tanker delays affect oil, LNG, and related goods." What Happens Next? Any final decision on Iran's response, whether negotiation or closing the Strait or other, however, will largely rest with the country's leader Ayatollah Ali Khamenei. The parliament vote to close the Strait merely advises him of the option to pursue.
